Dear Editor and reviewers,

We are very appreciated to receive your comments. We have revised our manuscript based on the comments carefully. The details are listed as follows:

Reviewer #1:

Specific Comments to Authors: This is a well written case report describing the loss of Her2 amplification in a patient with breast cancer after neoadjuvant chemotherapy and the authors went on to do a literature review of this phenomenon which has been shown in about 10% of patient in case series. Just a small point i would like the authors to clarify is with regards to the take home message, i think in this patient she continued to complete herceptin even after the her2 loss of amplification, so is the take home message that patient should continue to be treated based on initial her2 status pre neoadjuvant chemotherapy? I believe this point will be useful for readers if it is more explicitly clarified or stated.

Answer: Thanks for your suggestion. Despite observations revealing HER2 loss between initial biopsy and surgical specimens, management of patients with HER2+ breast cancer is frequently based on primary tumor characteristics. Furthermore, Several studies suggested that all subgroups of women seem to benefit from trastuzumab in exploratory subgroup analysis, regardless of changes in HER status. And the limitation was added.

Reviewer #2:

Specific Comments to Authors: The manuscript text is lacking spaces between words and sentences. Final Conclusion is missing after the discussion. After the abstract, there are paragraphs with no Heading (is INTRODUCTION missing?)

Answer: The revised manuscript have added spaces between words and sentences. We have rewritten these words to make our description clear.

That is all my responses. It will be our honor if this manuscript could be accepted by Journal of the World Journal of Clinical Cases. Thank you and hope to hear from you soon.

Yours sincerely,

Best regards

Nan-Lin Li